Moreover, metastatic CRC carrying KRAS mutations shows remarkable resistance to cetuximab due to the integrated activation of the RAS-RAF-MEK-ERK pathway 43, 44. This evidence concerns the gene MAP2K7 and colorectal carcinoma.